Exhibit 99.3 Unaudited Pro forma financial information for CytoDyn, Inc. and
Subsidiary as of July 17, 2006
CytoDyn, Inc
Unaudited Proforma Condensed Balance Sheet
Historical July 17, 2006
Unaudited
Assets Advanced Proforma
Influenza Proforma July 17,
CytoDyn, Inc Tech. Adjustments 2006
------------ ----------- ----------- -----------
Current Assets:
Cash ........................................... $ 59,709 $ 512,200 $ -- $ 571,909
Prepaid expenses ............................... 261,969 -- -- 261,969
Prepaid Sponsored Research ..................... -- 162,800 -- 162,800
------------ ----------- ----------- -----------
Total current assets ............... 321,678 675,000 -- 996,678
Furniture and equipment, less accumulated
depreciation of $2,204 ......................... 2,334 -- -- 2,334
------------ ----------- ----------- -----------
License Agreements ............................... -- 150,000 -- 150,000
Intangible asset, less accumulated
amortization of $1,722 ......................... 1,178 -- -- 1,178
Deposit .......................................... 495 -- -- 495
------------ ----------- ----------- -----------
$ 325,685 $ 825,000 $ -- $ 1,150,685
============ =========== =========== ===========
Liabilities and Shareholders' Deficit
Current Liabilities:
Accounts payable ............................... $ 86,753 $ 422,199 $ -- $ 508,952
Accrued liabilities ............................ 133,588 -- -- 133,588
Accrued interest payable ....................... 6,893 -- -- 6,893
Notes payable, net ............................. 134,500 -- -- 134,500
Derivative liability ........................... 27,319 -- -- 27,319
Indebtedness to related parties ................ 393,360 -- -- 393,360
------------ ----------- ----------- -----------
782,413 422,199 -- 1,204,612
Commitments and contingencies .................... 150,000 -- -- --
------------ ----------- ----------- -----------
932,413 422,199 -- 1,354,612
------------ ----------- ----------- -----------
Shareholders' deficit :
Preferred stock, no par value .................. -- -- -- --
Common Stock ................................... 3,062,566 1,000 -- 3,063,566
Additional paid-in capital ..................... 834,809 511,200 -- 1,346,009
Accumulated deficit ............................ (147,413) (109,399) -- (256,812)
Deficit accumulated during development stage ... (4,356,690) -- -- (4,356,690)
------------ ----------- ----------- -----------
(606,727) 402,801 -- (203,926)
------------ ----------- ----------- -----------
$ 325,685 $ 825,000 $ * $ 1,150,685
============ =========== =========== ===========
* The company has determined there are no proforma adjustments
CytoDyn, Inc
Unaudited Proforma Condensed Statement of Operations
For ther period June 1 - July 17, 2006
Advanced
Influenza Proforma Unaudited
CytoDyn Tech. Adjustments Proforma
------------ ------------ ----------- ------------
Operating expenses:
General and administrative ............... $ 145,837 $ -- $ -- $ 145,837
Stock-based compensation: ................ --
Research and Development ................. -- 109,399 -- 109,399
Total operating expenses ..... 145,837 109,399 -- 255,236
------------ ------------ ----------- ------------
Operating loss ............... (145,837) (109,399) -- (255,236)
Interest income ............................ 50 -- -- 50
Interest expense: .......................... --
Interest on convertible debt ............. (1,626) -- -- (1,626)
Discount on convertible debt (warrants) .. -- -- -- --
Discount on convertible debt ............. -- -- -- --
(beneficial conversion) ...... -- -- -- --
Other .................................... -- -- -- --
------------ ------------ ----------- ------------
Loss before income taxes ..... (147,413) (109,399) -- (256,812)
Income tax provision ....................... -- -- -- --
------------ ------------ ----------- ------------
Net loss ..................... $ (147,413) $ (109,399) $ -- $ (256,812)
============ ============ =========== ============
Basic and diluted loss per share ........... (0.01) $ (109.40) $ * $ (109.41)
============ ============ =========== ============
Basic and diluted weighted average
common shares outstanding .... 11,225,264 1,000 -- 11,226,264
============ ============ =========== ============
* The company has determined there are no proforma adjustments